ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / KYMR / news
QGEN (72) TECH (72) TWST (47) RGEN (61) ⌘ Pro Terminal →

Why KYMR Stock advanced +0.70% Today — RQD Quant Desk Flash

$127.51 +0.70% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $127.43

Kymera Therapeutics Inc. (KYMR) receives a Roarable Rating of D (Sell) and flashes a Red SELL / AVOID rating (51/100 RQD Confidence). Alongside weak composite pillar scores, our SEC filing scanner spotted paper earnings outpacing operating cash flow (+58.8% (NI vs OCF)).

ROARABLE D • SELL / AVOID Cap $10.81B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KYMR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KYMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Kymera Therapeutics Inc. (NASDAQ: KYMR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $127.51 (+0.70% 1D, market cap $10.81B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KYMR compare to QGEN and TECH in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KYMR carries a Roarable D (51/100 RQD), trailing P/E of 32.7x, gross margin of —, and ROIC of -21.4%. By comparison, QGEN (Qiagen N.V.) holds a B grade (72/100 RQD, P/E 24.4x, ROIC 8.0%, cap $10.35B) and TECH (Bio-Techne Corp) posts a B grade (72/100 RQD, P/E 155.3x, ROIC 3.4%, cap $11.39B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while QGEN leads on capital efficiency (8.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KYMR?
▼

Per KYMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001815442), Kymera Therapeutics Inc. generated $39.2M in revenue (-16.7% YoY), $311.4M in net income, and -$234.3M in free cash flow against $1.74B in total assets and $73.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $127.43 (-0.06%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 51/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.3% avg 90D alpha vs SPY • 49.7% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510051
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Cash (5)Whales (18)SEC (13)Macro (10)CEO (5)
Each axis scored 0–20
12M PRICE TARGET CONE-3.2% Base Target
$146 Bull$123 Base$96 Bear
📬 FREE KYMR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KYMR)Realized 20D OHLCV Swing Band: ±9.8%
Deterministic 5-Pillar Attribution (51/100 Composite)
🔍 WHY KYMR SCORES 51/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+18/20 pts (35% of score)

20D Institutional Volume Accumulation (±9.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (25% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
43
Grade D$106.83+5.4% Next Q
Q2 (-2Q)
46
Grade D$112.63+8.8% Next Q
Q3 (-1Q)
48
Grade D$122.51+4.1% Next Q
Current
51
Grade D$127.51-1.3% Hist 90D α
Trajectory: D (43) → D (51)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a KYMR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While KYMR currently carries a cautious 51/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Big institutional funds and options desks are actively positioning on the bullish side.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($115.00) and Max Pain ($133.89) forces dealer call-delta covering toward $145.72.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KYMR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KYMR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 51%NO 49%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why KYMR Stock advanced +0.70% Today — RQD Quant Desk Flash

Kymera Therapeutics Inc. (KYMR) advanced +0.70% to $127.51, trading at 97% of its 52-week range ($55.66 – $130.05). Weak 51/100 RQD score compounded by SEC accrual divergence (+58.8% (NI vs OCF)).

  • ▸Technical Tape: Trading at 97% of its 52-week range ($55.66 – $130.05) with RSI-14 at 66 (BULLISH MOMENTUM).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±9.8% around $127.51 (no active unusual options sweep snapshot on file).
  • ▸Primary SEC / Cross-Feed Trigger: KYMR Accounting Gap: Net Income (+39.1%) Outpaced OCF (-19.7%) With +48.5% Working-Capital Build
Live KYMR Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KYMR)

  • ✓Walkthrough of KYMR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KYMR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +52.54%⚡ TESTING RESISTANCE
2026-11-03O $122.6H $127.5L $122.6C $127.5VOL 1.59M
RES: $127.7SUP: $102.8SMA50: $115.0SMA200: $97.23
$134.4$116.3$98.09$79.91$61.74RES $127.7SUP $102.8$127.52026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KYMR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KYMR Butterfly Map → + Track KYMR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth

vs. -16.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on KYMR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KYMR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KYMR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KYMR)

Health Care Rank #249 of 1015 ⚔️ QGEN vs KYMR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KYMR vs. QGEN, TECH, TWST, RGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Kymera Therapeutics Inc. (KYMR) ranks #249 by composite RQD confidence (51/100, grade D) and #99 by equity capitalization ($10.81B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while QGEN leads on capital efficiency and profitability with 8.0% ROIC and 62.2% gross margin. QGEN currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with KYMR at 51/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KYMR ACTIVE
Kymera Therapeutics Inc.
D 51/100 32.7x — -21.4% +0.70% $10.81B Benchmark Subject
QGEN
Qiagen N.V.
B 72/100 24.4x 62.2% 8.0% +0.26% $10.35B /qgen-vs-kymr →
TECH
Bio-Techne Corp
B 72/100 155.3x 64.8% 3.4% +0.01% $11.39B /tech-vs-kymr →
TWST
Twist Bioscience Corporation
D 47/100 — 94.2% -11.7% -15.54% $10.13B /twst-vs-kymr →
RGEN
Repligen Corporation
C- 61/100 — 88.2% 2.3% -2.25% $10.03B /rgen-vs-kymr →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001815442 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kymera Therapeutics Inc. (KYMR) reported GAAP revenue of $39.2M (-16.7% vs. FY2024 revenue of $47.1M , and -50.1% cumulative change since FY2023) , GAAP net income of $311.4M, operating cash flow of -$232.9M, and free cash flow of -$234.3M (-13.0% YoY). On the balance sheet, KYMR closed FY2025 with $1.74B in total assets against $73.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $39.2M $311.4M -$232.9M -$234.3M $1.74B $73.4M
FY2024 (FY) 2024-12-31 $47.1M $223.9M -$194.5M -$207.3M $978.0M $64.1M
FY2023 (FY) 2023-12-31 $78.6M $147.0M -$102.8M -$106.4M $5.61B $1.31B

3. KYMR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KYMR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Kymera Therapeutics Inc. (NASDAQ: KYMR) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 51/100 at a spot price of $127.51 (+0.70% 1D, market cap $10.81B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 18/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 5/20. Active quantitative signal ACCOUNTING_MIRAGE (BEARISH, conviction undefined/100) notes: undefined.

How does KYMR compare to QGEN and TECH in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KYMR carries a Roarable D (51/100 RQD), trailing P/E of 32.7x, gross margin of —, and ROIC of -21.4%. By comparison, QGEN (Qiagen N.V.) holds a B grade (72/100 RQD, P/E 24.4x, ROIC 8.0%, cap $10.35B) and TECH (Bio-Techne Corp) posts a B grade (72/100 RQD, P/E 155.3x, ROIC 3.4%, cap $11.39B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while QGEN leads on capital efficiency (8.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KYMR?

Per KYMR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001815442), Kymera Therapeutics Inc. generated $39.2M in revenue (-16.7% YoY), $311.4M in net income, and -$234.3M in free cash flow against $1.74B in total assets and $73.4M in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KYMR trading relative to its 50-day, 200-day, and 52-week technical levels?

KYMR last traded at $127.51 (+0.70% on volume of 1,294,674 shares), positioning the stock +10.88% above its 50-day simple moving average ($115.00) and +31.14% above its 200-day simple moving average ($97.23). Across its 52-week range of $55.66 to $130.05, KYMR sits at the 96.6% percentile with a 14-day RSI of 66.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±9.8% ($115.01 to $140.01).

Direct Sub-Reports: KYMR RQD Cockpit KYMR 12M Forecast KYMR Earnings & Move KYMR Dividends & DRIP KYMR Insiders & 13F KYMR Whale Options KYMR Profit Sankey KYMR News & Why
ROARABLE RATING BRIEF • RQD 51/100 (D) ✓ SEC XBRL & RQD VERIFIED

KYMR — Kymera Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Kymera Therapeutics Inc. (KYMR) earns a live Roarable RQD composite score of 51/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $127.51 (+0.70% 1D, market capitalization $10.81B).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -21.4%, gross margin of —, operating margin of -60.0%, and free cash flow yield of -2.30%.
  • Whale 13F & Options Flow (18/20) + Insider Conviction (5/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (13/20): Incorporates a 0.95x equity beta, Altman Z-Score of 26.00, Piotroski F-Score of 4/9, and Debt/Equity of 0.04x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Kymera Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Biological Products (No Diagnostic Substances) industry,. The profile identifies a market capitalization of $10.2B. Gross margin is reported as 0%, and the financials show revenue of $39.2M for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Kymera Therapeutics Inc. (KYMR) reported $39.2M in annual revenue (up from $47.1M in FY2024, -16.7% YoY) and $311.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($78.6M revenue, $147.0M net income) through FY2025, KYMR scaled operating cash flow to -$232.9M and free cash flow to -$234.3M, backed by $1.74B in total assets against $73.4M in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 51/100): Big institutional funds and options desks are actively positioning on the bullish side. Free cash flow yield of -2.30% and institutional whale pillar of 18/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 18/20, sustained execution supports upside toward the upper end of the $55.66 – $130.05 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: SEC Accrual Watch: Headline earnings grew faster than operating cash flow—monitor working-capital conversion. Investors must weigh 32.7x trailing P/E against -60.0% operating margins and a 0.95x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are therefore — The only cross-company signal is the accrual mismatch described above. The investor implication is that a 10-Q cash realization check is the nearest test: if working-capital build persists while operating cash flow stays negative, the bearish signal would be reinforced.

  • Key Question #1: Can KYMR sustain or expand its -60.0% operating margin and -21.4% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $39.2M and free cash flow of -$234.3M, how will capital allocation balance growth reinvestment against $73.4M in total debt?
  • Key Question #3: How sensitive is KYMR's 30.4x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.95x)?

KYMR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kymera Therapeutics Inc. (KYMR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KYMR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KYMR Bull vs. Bear Conversation Board — What's Your Call at $127.51?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KYMR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KYMR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $150.69 (+19.0%)
📌 Pinned Debate

Institutional 13F accumulation and options positioning score 17 of 20, the strongest pillar in the RQD rating, alongside a 0.04 Debt/Eq

Don't sleep on KYMR's setup in Health Care. Institutional 13F accumulation and options positioning score 17 of 20, the strongest pillar in the RQD rating, alongside a 0.04 Debt/Equity and an Altman Z of 26.. Beta of 0.95 means it moves fast when momentum turns, and the 5-pillar RQD gauge (51/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

Both sides have a point here — KYMR's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $98.77 (-22.0%)
Spot @ $126.63

Operating income of -$349.4M, negative free cash flow of -$234.3M, and a +58.8% cash conversion gap leave reported profit unsupported b

I respect the product at Kymera Therapeutics Inc., but the stock at $126.63 is a different story. Operating income of -$349.4M, negative free cash flow of -$234.3M, and a +58.8% cash conversion gap leave reported profit unsupported by cash generation.. FCF yield is -2.3% and RQD sits at 51/100 (D) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%